Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 4/20 | 0.33 |
| ▸ | CFTR | P13569 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25116014 | 0.93 | GABRA5 (0.32) | GABRA5MAPTLMNA | |
| SCHEMBL23905718 | 0.93 | CFTR (0.32) | GABRA5CFTRMAPT | |
| SCHEMBL23905406 | 0.92 | GABRA5 (0.34) | GABRA5CFTRMAPTPDE4B | |
| SCHEMBL25116477 | 0.87 | CFTR (0.32) | GABRA5CFTRMAPTKDM4EALDH1A1 | |
| SCHEMBL24988033 | 0.86 | GABRA5 (0.35) | GABRA5CFTRMAPT | |
| SCHEMBL23905315 | 0.84 | GABRA5 (0.34) | GABRA5CFTR | |
| SCHEMBL23905865 | 0.84 | GABRA5 (0.34) | GABRA5CFTR | |
| SCHEMBL24988035 | 0.84 | ALDH1A1 (0.32) | GABRA5CFTRMAPTALDH1A1HPGD | |
| SCHEMBL23905868 | 0.84 | GABRA5 (0.34) | GABRA5CFTRKDM4EALDH1A1HPGD | |
| SCHEMBL23905870 | 0.84 | GABRA5 (0.34) | GABRA5CFTRKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230108803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230108803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ACE, HPRT1, ACE2 | GABRA5 3773/4885CFTR 283/4885MAPT 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.